000			02127 a2200625 4500
005			20250517092415.0
264		0	_c20171031
008			201710s 0 0 eng d
022			_a1463-1326
024	7		_a10.1111/dom.12680 _2doi
040			_aNLM _beng _cNLM
100	1		_aDutour, A
245	0	0	_aExenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. _h[electronic resource]
260			_bDiabetes, obesity & metabolism _c09 2016
300			_a882-91 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial
650	0	4	_aAdipose Tissue _xdiagnostic imaging
650	0	4	_aDiabetes Mellitus, Type 2 _xcomplications
650	0	4	_aExenatide
650	0	4	_aFatty Liver _xcomplications
650	0	4	_aFemale
650	0	4	_aGlycated Hemoglobin _xmetabolism
650	0	4	_aHeart _xdiagnostic imaging
650	0	4	_aHumans
650	0	4	_aHypoglycemic Agents _xtherapeutic use
650	0	4	_aLiver _xdiagnostic imaging
650	0	4	_aMagnetic Resonance Imaging
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMyocardium _xmetabolism
650	0	4	_aObesity _xcomplications
650	0	4	_aPancreas _xdiagnostic imaging
650	0	4	_aPeptides _xtherapeutic use
650	0	4	_aPericardium _xdiagnostic imaging
650	0	4	_aPostprandial Period
650	0	4	_aProton Magnetic Resonance Spectroscopy
650	0	4	_aTreatment Outcome
650	0	4	_aTriglycerides _xmetabolism
650	0	4	_aVenoms _xtherapeutic use
700	1		_aAbdesselam, I
700	1		_aAncel, P
700	1		_aKober, F
700	1		_aMrad, G
700	1		_aDarmon, P
700	1		_aRonsin, O
700	1		_aPradel, V
700	1		_aLesavre, N
700	1		_aMartin, J C
700	1		_aJacquier, A
700	1		_aLefur, Y
700	1		_aBernard, M
700	1		_aGaborit, B
773	0		_tDiabetes, obesity & metabolism _gvol. 18 _gno. 9 _gp. 882-91
856	4	0	_uhttps://doi.org/10.1111/dom.12680 _zAvailable from publisher's website
999			_c25951360 _d25951360